Brisbane Broncos Ltd (BBL)
Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026
Key indicators
| Last close | AUD 1.450 |
|---|---|
| 52-week range | 1.150 – 1.886 |
| Return, 1 month / 3 months | −12.1% / +3.9% |
| Return, 1 year / 3 years | +24.0% / +54.4% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 65.3% |
| Worst drawdown (1 year) | -39.0% |
| Average daily value traded | 0.02M AUD |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Brisbane Broncos is a professional rugby league football club based in Brisbane, Australia. The club fields teams in the National Rugby League competition and related grades, and its business centres on match-day operations, memberships, merchandise and sponsorship arrangements with corporate partners. It draws supporters from across Queensland and beyond, and its commercial activities are tied to the profile of its football teams and the stadium events it hosts.
Brisbane Broncos Ltd trades under the code BBL on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Brisbane Broncos Ltd (BBL) trades on the Australian Securities Exchange in Australia. It last closed at AUD 1.450 on 19 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 659 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 24.0% and over the last three months it rose 3.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 66 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -7.1% | ||
| From 52-week high | -23.1% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.9% | ||
| 6-month return | -15.5% | ||
| 12-month return, skipping the last month | 41.1% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 65.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.0% | ||
| Liquidity | 41 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M AUD | ||
| Zero-volume days | 1.7% | ||
| Income | 34 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.0% |
|---|---|
| 1 month | −12.1% |
| 3 months | +3.9% |
| 6 months | −15.5% |
| 1 year | +24.0% |
| 3 years | +54.4% |
| 5 years | +71.2% |
Signals
| 50-day / 200-day average | 1.526 / 1.562 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.041 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Mar 2026 | AUD 0.0300 |
| 19 Mar 2025 | AUD 0.0200 |
| 20 Mar 2024 | AUD 0.0150 |
| 21 Mar 2023 | AUD 0.0150 |
| 22 Mar 2022 | AUD 0.0100 |
| 23 Mar 2021 | AUD 0.0050 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.